Barclays’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.71M | Buy |
36,199
+8,046
| +29% | +$517K | ﹤0.01% | 2188 |
|
|
2026
Q1 | $1.59M | Sell |
28,153
-96,076
| -77% | -$6.26M | ﹤0.01% | 2499 |
|
|
2025
Q4 | $9.96M | Buy |
124,229
+4,921
| +4% | +$331K | ﹤0.01% | 1679 |
|
|
2025
Q3 | $5.82M | Sell |
119,308
-100,499
| -46% | -$6.22M | ﹤0.01% | 2074 |
|
|
2025
Q2 | $16.4M | Buy |
219,807
+49,942
| +29% | +$3.31M | ﹤0.01% | 1244 |
|
|
2025
Q1 | $10.8M | Buy |
169,865
+47,730
| +39% | +$3.25M | ﹤0.01% | 1349 |
|
|
2024
Q4 | $9.54M | Buy |
122,135
+19,602
| +19% | +$1.57M | ﹤0.01% | 1610 |
|
|
2024
Q3 | $8.24M | Buy |
102,533
+67,470
| +192% | +$5.45M | ﹤0.01% | 1621 |
|
|
2024
Q2 | $2.9M | Sell |
35,063
-68,802
| -66% | -$6.05M | ﹤0.01% | 1877 |
|
|
2024
Q1 | $8.86M | Sell |
103,865
-15,034
| -13% | -$1.18M | ﹤0.01% | 1481 |
|
|
2023
Q4 | $10.2M | Buy |
118,899
+81,303
| +216% | +$7.03M | ﹤0.01% | 1503 |
|
|
2023
Q3 | $3.37M | Sell |
37,596
-6,059
| -14% | -$541K | ﹤0.01% | 1572 |
|
|
2023
Q2 | $3.72M | Buy |
43,655
+5,606
| +15% | +$474K | ﹤0.01% | 1520 |
|
|
2023
Q1 | $3.15M | Buy |
38,049
+15,572
| +69% | +$1.26M | ﹤0.01% | 1865 |
|
|
2022
Q4 | $1.77M | Buy |
22,477
+16,427
| +272% | +$1.32M | ﹤0.01% | 2344 |
|
|
2022
Q3 | $447K | Buy |
6,050
+1,614
| +36% | +$116K | ﹤0.01% | 2770 |
|
|
2022
Q2 | $289K | Sell |
4,436
-7,822
| -64% | -$463K | ﹤0.01% | 3222 |
|
|
2022
Q1 | $776K | Sell |
12,258
-62,235
| -84% | -$3.38M | ﹤0.01% | 2588 |
|
|
2021
Q4 | $3.95M | Buy |
74,493
+17,293
| +30% | +$1.05M | ﹤0.01% | 1876 |
|
|
2021
Q3 | $4.04M | Buy |
57,200
+19,084
| +50% | +$1.2M | ﹤0.01% | 1771 |
|
|
2021
Q2 | $2.54M | Buy |
38,116
+12,717
| +50% | +$900K | ﹤0.01% | 2038 |
|
|
2021
Q1 | $2.82M | Buy |
25,399
+23,993
| +1,706% | +$2.97M | ﹤0.01% | 1995 |
|
|
2020
Q4 | $167K | Sell |
1,406
-385
| -21% | -$41.4K | ﹤0.01% | 3869 |
|
|
2020
Q3 | $157K | Sell |
1,791
-16,239
| -90% | -$1.42M | ﹤0.01% | 3999 |
|
|
2020
Q2 | $1.61M | Sell |
18,030
-1,335
| -7% | -$135K | ﹤0.01% | 2323 |
|
|
2020
Q1 | $1.93M | Sell |
19,365
-40,045
| -67% | -$4.34M | ﹤0.01% | 2324 |
|
|
2019
Q4 | $6.83M | Buy |
59,410
+23,880
| +67% | +$2.89M | ﹤0.01% | 1711 |
|
|
2019
Q3 | $4.48M | Sell |
35,530
-5,238
| -13% | -$665K | ﹤0.01% | 1960 |
|
|
2019
Q2 | $4.91M | Sell |
40,768
-4,702
| -10% | -$463K | ﹤0.01% | 1884 |
|
|
2019
Q1 | $3.98M | Buy |
45,470
+31,421
| +224% | +$2.86M | ﹤0.01% | 1857 |
|
|
2018
Q4 | $1.41M | Sell |
14,049
-28,064
| -67% | -$2.95M | ﹤0.01% | 2774 |
|
|
2018
Q3 | $4.83M | Sell |
42,113
-3,505
| -8% | -$363K | ﹤0.01% | 1855 |
|
|
2018
Q2 | $4.09M | Buy |
45,618
+28,453
| +166% | +$2.4M | ﹤0.01% | 1897 |
|
|
2018
Q1 | $1.26M | Buy |
17,165
+5,729
| +50% | +$393K | ﹤0.01% | 2950 |
|
|
2017
Q4 | $664K | Buy |
11,436
+8,294
| +264% | +$437K | ﹤0.01% | 3529 |
|
|
2017
Q3 | $141K | Sell |
3,142
-10,187
| -76% | -$423K | ﹤0.01% | 4682 |
|
|
2017
Q2 | $527K | Buy |
13,329
+11,927
| +851% | +$490K | ﹤0.01% | 3470 |
|
|
2017
Q1 | $57K | Buy |
1,402
+255
| +22% | +$9.96K | ﹤0.01% | 5258 |
|
|
2016
Q4 | $46K | Sell |
1,147
-1,047
| -48% | -$39.5K | ﹤0.01% | 5216 |
|
|
2016
Q3 | $79K | Sell |
2,194
-2,162
| -50% | -$74.2K | ﹤0.01% | 4666 |
|
|
2016
Q2 | $126K | Sell |
4,356
-36,341
| -89% | -$1.1M | ﹤0.01% | 4243 |
|
|
2016
Q1 | $1.38M | Buy |
40,697
+33,714
| +483% | +$1.09M | ﹤0.01% | 2262 |
|
|
2015
Q4 | $224K | Buy |
6,983
+6,367
| +1,034% | +$207K | ﹤0.01% | 3815 |
|
|
2015
Q3 | $19K | Sell |
616
-376
| -38% | -$14.2K | ﹤0.01% | 5482 |
|
|
2015
Q2 | $40K | Sell |
992
-641
| -39% | -$27K | ﹤0.01% | 5285 |
|
|
2015
Q1 | $71K | Sell |
1,633
-1,331
| -45% | -$55.6K | ﹤0.01% | 5053 |
|
|
2014
Q4 | $109K | Buy |
2,964
+1,076
| +57% | +$39.4K | ﹤0.01% | 5135 |
|
|
2014
Q3 | $64K | Buy |
1,888
+963
| +104% | +$34.4K | ﹤0.01% | 5668 |
|
|
2014
Q2 | $32K | Sell |
925
-1,263
| -58% | -$42.2K | ﹤0.01% | 6238 |
|
|
2014
Q1 | $70K | Sell |
2,188
-17,737
| -89% | -$678K | ﹤0.01% | 5723 |
|
|
2013
Q4 | $836K | Sell |
19,925
-28,455
| -59% | -$1.17M | ﹤0.01% | 3576 |
|
|
2013
Q3 | $1.89M | Sell |
48,380
-23,939
| -33% | -$1M | ﹤0.01% | 2648 |
|
|
2013
Q2 | $2.99M | Buy |
+72,319
| New | +$2.93M | ﹤0.01% | 2101 |
|
Other funds holding HAE
AI
Barclays's HAE Position: Q2 2026 in Review
Barclays increased its Haemonetics (HAE) stake by 29% in Q2 2026, buying an estimated $517K and bringing the position to 36,199 shares worth $2.71M. The position accounts for ﹤0.01% of the portfolio, ranked #2188.
Barclays first reported a position in HAE in Q2 2013 and has held it in 53 quarters since. The position peaked at $16.4M in Q2 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.
- Barclays held 36,199 shares of Haemonetics worth $2.71M as of Q2 2026.
- Barclays bought 8,046 Haemonetics shares in Q2 2026, an estimated $517K.
- Haemonetics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2188 holding.
- Barclays first reported a position in Haemonetics in Q2 2013 and has held it in 53 quarters since.
- Barclays's Haemonetics position peaked at $16.4M in Q2 2025.
- 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.